Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 0.96 |
| ▸ | HTR7 | P34969 | 3/20 | 0.96 |
| ▸ | HTR6 | P50406 | 2/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | PGR | P06401 | 1/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | GOT1 | P17174 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL1164202 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL122875 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL29594402 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL10324884 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL6061373 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL2978306 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL2978308 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118975981-A | Ziprasidone hydrochloride suspension and preparation method thereof | 北京万全阳光医学技术有限公司 | 2024-11-19 | — | — | CN | claimed |
| US-7777037-B2 | Ziprasidone process | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-08-17 | — | — | US | claimed |
| WO-2010073255-A1 | PROCESS FOR PREPARING ZIPRASIDONE | CADILA HEALTHCARE LIMITED (IN) | 2010-07-01 | — | — | WO | claimed |
| EP-2197446-A2 | PREPARATION OF ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE | Dr. Reddy's Laboratories Ltd. (IN) | 2010-06-23 | — | — | EP | claimed |
| US-20090163513-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2009-06-25 | — | — | US | claimed |
| WO-2009032558-A2 | PREPARATION OF ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-12 | — | — | WO | claimed |
| WO-2007126322-A1 | A METHOD FOR OBTAINING A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE AGENT ZIPRASIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PLIVAKRAKÓW, ZAKLADY FARMACEUTYCZNE S.A. (PL) | 2007-11-08 | — | — | WO | claimed |
| EP-1841764-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2007-10-10 | — | — | EP | claimed |
| US-20070225295-A1 | Ziprasidone Hydrochloride Polymorph and Process for Its Preparation | DIPHARMA S.P.A. (IT) | 2007-09-27 | — | — | US | claimed |
| WO-2007102038-A1 | ZIPRASIDONE FORMULATIONS | WOCKHARDT LIMITED (IN) | 2007-09-13 | — | — | WO | claimed |
| EP-0965343-B1 | Ziprasidone formulations | PFIZER PROD INC (US) | 2003-05-21 | — | — | EP | claimed |
| US-6558435-B2 | Reactive crystallization method to improve particle size | PFIZER, INC. | 2003-05-06 | — | — | US | claimed |
| US-6387904-B2 | COMPOUND CONTAINING PIPERAZINE RING | PFIZER INC | 2002-05-14 | — | — | US | claimed |
| US-20020016498-A1 | Reactive crystallization method to improve particle size | PFIZER PRODUCTS INC. | 2002-02-07 | — | — | US | claimed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | claimed |
| CN-1326803-A | Reaction crystallizing method for improving grain size | PFIZER (US) | 2001-12-19 | — | — | CN | claimed |
| EP-1157726-A1 | Reactive crystallization method to improve particle size | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| US-6150366-A | CRYSTALLINE ZIPRASIDONE FREE BASE OR CRYSTALLINE ZIPRASIDONE HYDROCHLORIDE PARTICLES WITH SPECIFIC PARTICLE SIZE ARE USEFUL AS ANTIPSYCHOSIS AGENT | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0965343-A2 | Ziprasidone formulations | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | HTR2A 2202/4885DRD2 3644/4885HTR2C 3778/4885 |
| US-20090163513-A1 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES | SIGMAR1, SI, SLC39A11 | HTR2A 31/4885DRD2 66/4885HTR2C 27/4885 |
| US-20070225295-A1 | Ziprasidone Hydrochloride Polymorph and Process for Its Preparation | HAMP, SLC39A3, REN | HTR2A 92/4885DRD2 813/4885HTR2C 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.